Spherix Global Insights

January 22, 2018

Ustekinumab Makes Inroads in Crohn’s Disease – Docs opt for psoriasis drug when anti-TNF agents fail

From: MedPage Today
Byy: Ed Susman, Contribution Writer, MedPAge Today

LAS VEGAS — TNF inhibitors remain the predominant treatment in Crohn’s disease, but ustekinumab (Stelara) has been quickly adopted by clinicians, accounting for about one in five recently switched patients, researchers reported here.

The agent received FDA approval in 2016 for the treatment of moderately to severely active Crohn’s disease in adults who have failed or were intolerant to treatment with immunomodulators or corticosteroids but never failed treatment with a TNF blocker, or who failed or were intolerant to treatment with one or more TNF blockers…(read more).